APVO · Aptevo Therapeutics Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $3.92M | - | $4.04M | $3.33M | $3.63M | - | $3.10M | $3.64M | $3.75M | - |
| SG&A | $2.91M | - | $3.57M | $2.90M | $2.85M | - | $2.11M | $2.38M | $3.23M | - |
| Total Operating Expenses | - | - | - | - | - | - | - | - | - | - |
| D&A | $35.0K | - | - | - | $61.0K | - | - | - | $106.0K | - |
| Operating Income | ($6.84M) | - | ($7.61M) | ($6.23M) | ($6.48M) | - | ($5.21M) | ($6.02M) | ($6.98M) | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($6.70M) | - | ($7.55M) | ($6.20M) | ($6.41M) | - | ($5.10M) | ($5.88M) | ($6.83M) | - |
| EPS - Basic | ($6.41) | - | ($40.14) | ($151.20) | ($1580.40) | - | ($6393.60) | ($22244.40) | ($132534.00) | - |
| EPS - Diluted | ($6.41) | - | ($40.14) | ($151.20) | ($1580.40) | - | ($6393.60) | ($22244.40) | ($132534.00) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $14.53M | $21.62M | $21.06M | $9.41M | $2.14M | $8.71M | $7.75M | $8.07M | $10.25M | $16.90M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $890.0K | $877.0K | - | - | - | $1.24M | - | - | - | - |
| Current Assets | $15.98M | $23.08M | $22.65M | $11.08M | $3.61M | $10.66M | $10.01M | $9.58M | $12.07M | $19.07M |
| Total Assets | $19.90M | $27.19M | $27.00M | $15.62M | $8.34M | $15.59M | $15.15M | $14.92M | $17.63M | $24.84M |
| Current Liabilities | $4.76M | $6.05M | $5.61M | $4.89M | $5.39M | $6.21M | $5.88M | $5.42M | $6.30M | $7.22M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | $0 |
| Total Liabilities | $8.29M | $9.81M | $9.60M | $9.10M | $9.81M | $10.84M | $10.73M | $10.46M | $11.53M | $12.62M |
| Stockholders' Equity | $11.61M | $17.38M | $17.39M | $6.52M | ($1.47M) | $4.75M | $4.42M | $4.46M | $6.10M | $12.22M |
| Retained Earnings | ($281.91M) | ($275.12M) | ($269.22M) | ($260.19M) | ($253.99M) | ($247.58M) | ($241.26M) | ($236.16M) | ($230.28M) | ($223.45M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($7.96M) | - | - | - | ($6.58M) | - | - | - | ($6.65M) | - |
| Investing Cash Flow | $0 | - | - | - | - | - | - | - | - | - |
| Financing Cash Flow | $871.0K | - | - | - | $0 | - | - | - | ($3.0K) | - |
| CapEx | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -33.6% | - | -28.0% | -39.7% | -76.8% | - | -33.7% | -39.4% | -38.8% | - |
| Return on equity | -57.7% | - | -43.4% | -95.1% | 435.0% | - | -115.4% | -131.8% | -112.0% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 3.36 | 3.82 | 4.03 | 2.27 | 0.67 | 1.72 | 1.70 | 1.77 | 1.92 | 2.64 |
| Quick ratio | 3.36 | 3.82 | 4.03 | 2.27 | 0.67 | 1.72 | 1.70 | 1.77 | 1.92 | 2.64 |
| Cash ratio | 3.05 | 3.57 | 3.75 | 1.92 | 0.40 | 1.40 | 1.32 | 1.49 | 1.63 | 2.34 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | 0.00 |
| Debt / Assets | - | - | - | - | - | - | - | - | - | 0.00 |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.71 | 1.56 | 1.55 | 2.39 | -5.66 | 3.28 | 3.43 | 3.34 | 2.89 | 2.03 |
| Liabilities / Assets | 0.42 | 0.36 | 0.36 | 0.58 | 1.18 | 0.70 | 0.71 | 0.70 | 0.65 | 0.51 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 0.4x | - | 6.1x | 6.2x | - | - | 5721.9x | 3214.6x | 7029.5x | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -5.5% | - | -46.0% | -3.4% | 7.2% | - | 20.5% | 26.3% | 10.0% | - |
| Net income growth (YoY) | -4.5% | - | -48.0% | -5.5% | 6.2% | - | 19.5% | 26.0% | - | - |
| EPS growth (YoY) | 99.6% | - | 99.4% | 99.3% | 98.8% | - | -1278620.0% | -1808387.8% | -8550480.6% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | - | 265.5% | 293.5% | 46.2% | - | -61.1% | -70.0% | -72.5% | -73.8% | -32.0% |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Aptevo Therapeutics Inc. against the 5 most active filers in the same SIC group.